Healthcare / Pharmaceutical RetailersTokyo
$823.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $771.0M · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.3B
P/E
20.8x
↑EV/EBITDA
9.2x
↓ROE
7.8%
↑Gross Margin
25.5%
↓Debt/Equity
1.76
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.5%
FCF CAGR
—
FCF margin
0.8%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $100.17B · net income $767.0M · FCF $771.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100.17B | $100.17B | $95.52B | $87.48B | $82.91B |
| Net Income | $767.0M | $767.0M | $470.0M | $87.0M | $316.0M |
| EBITDA | $2.80B | $2.80B | $2.36B | $1.58B | $1.73B |
| EPS | 55.54 | 55.54 | 34.07 | 6.32 | 22.98 |
| Gross Margin | 25.5% | 25.5% | 24.7% | 24.3% | 24.2% |
| Operating Margin | 1.7% | 1.7% | 1.4% | 0.3% | 0.9% |
| Net Margin | 0.8% | 0.8% | 0.5% | 0.1% | 0.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.76 | 1.76 | 1.91 | 2.07 | 1.58 |
| Current Ratio | 1.06 | 1.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $771.0M | $771.0M | $1.85B | $-3.94B | $-750.0M |
| Returns | |||||
| ROE | 7.8% | 7.8% | 5.1% | 1.0% | 3.6% |
| Valuation | |||||
| P/E | 20.79 | 20.79 | 25.36 | 117.72 | 28.72 |
| EV/EBITDA | 9.25 | 9.25 | 11.27 | 16.48 | 11.60 |
| P/B | 1.16 | 1.16 | 1.31 | 1.18 | 1.03 |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 9.2% | 5.5% | — |
| EPS Growth | 63.0% | 63.0% | 439.1% | -72.5% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
9.6%
EPS terminal req.
$73.03
Spread vs growth
53.5%
5Y implied EPS CAGR
9.7%
EPS terminal req.
$88.36
Spread vs growth
53.3%
10Y implied EPS CAGR
9.9%
EPS terminal req.
$142.31
Spread vs growth
53.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.8%
Start / end P/E
25.2x → 14.8x
EPS bridge
34.07 → 55.54
Residual
-26.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.